The emerging role of histone deacetylase inhibitors in treating T-cell lymphomas.
about
Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study.Expression of histone deacetylases in diffuse large B-cell lymphoma and its clinical significanceCardiac HDAC6 catalytic activity is induced in response to chronic hypertensionSyntheses and discovery of a novel class of cinnamic hydroxamates as histone deacetylase inhibitors by multimodality molecular imaging in living subjects.Histone deacetylases inhibitor Trichostatin A ameliorates DNFB-induced allergic contact dermatitis and reduces epidermal Langerhans cells in miceRomidepsin: a histone deacetylase inhibitor for refractory cutaneous T-cell lymphoma.
P2860
The emerging role of histone deacetylase inhibitors in treating T-cell lymphomas.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The emerging role of histone deacetylase inhibitors in treating T-cell lymphomas.
@en
The emerging role of histone deacetylase inhibitors in treating T-cell lymphomas.
@nl
type
label
The emerging role of histone deacetylase inhibitors in treating T-cell lymphomas.
@en
The emerging role of histone deacetylase inhibitors in treating T-cell lymphomas.
@nl
prefLabel
The emerging role of histone deacetylase inhibitors in treating T-cell lymphomas.
@en
The emerging role of histone deacetylase inhibitors in treating T-cell lymphomas.
@nl
P2860
P1476
The emerging role of histone deacetylase inhibitors in treating T-cell lymphomas.
@en
P2093
Steven M Horwitz
P2860
P2888
P356
10.1007/S11899-010-0067-5
P577
2011-03-01T00:00:00Z